QOL – Page 2 – malecare.org

Tri-weekly Docetaxel Versus Bi-weekly Docetaxel as a Treatment for Advanced Castration Resistant Prostate Cancer: Quality of Life Analysis

Administering chemotherapy using docetaxel (taxotere or T) on a bi-weekly basis with prednisone improved progression free survival and overall survival when compared with the standard tri-weekly schedule for men with advanced castration resistant prostate cancer (CRPC) (Lancet Oncol. 2013;14:117-124). However, quality of life (QoL) differences have not been evaluated. In a trial to evaluate the [...]

By Malecare|2017-10-19T10:48:30-04:00March 20th, 2014|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|2 Comments

Hot Flash Treatments Used for Women Don’t Work in Men with Advanced Prostate Cancer on ADT

Those of us with advanced prostate cancer who have used hormone therapy (ADT) often find that we are plagued with hot flashes that are detrimental to our quality of life (QOL). I believe that hot flashes are the most common side effect complained about by men who are on ADT, in the scheme of seriousness [...]

By Malecare|2013-11-15T10:36:30-05:00November 15th, 2013|Advanced Prostate Cancer, Diet, Diet and Supplements, Drugs & Treatments, Hormone Therapy, Hot Flashes, Quality of Life, supplements, Uncategorized, Understanding APC|1 Comment

Psycho-Oncologic Interventions May Improve Patients’ Distress and Quality of Life

According to a study published in the Feb. 20 issue of the Journal of Clinical Oncology adults with cancer can experience improvements in their emotional distress levels and in their quality of life through the use of psycho-oncologic interventions, such as relaxation, individual and group psychotherapy, and psychoeducation. Hermann Faller, M.D., Ph.D., of the University [...]

By Malecare|2013-03-14T07:31:04-04:00March 14th, 2013|Advanced Prostate Cancer, General Information, Germany, Research, Uncategorized|0 Comments

New Research Contradicts Prior Understanding – Intermittent Hormone Therapy for Prostate Cancer Inferior to Continuous Therapy

At the American Society for Clinical Oncology's (ASCO) meeting there was an upsetting plenary presentation made on June 3. Data was presented by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center. Dr. Hussain discussed the findings from the phase III clinical trial SWOG-9346, the largest such study to date [...]

By Malecare|2017-10-19T10:51:07-04:00June 4th, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Uncategorized, Understanding APC|1 Comment

From ASCO: Enzalutamide (MDV-3100) Data Relating to Quality of Life Measures and Extension of Time to First Skeletal-Related Event

The American Society of Clinical Oncologists (ASCO) has started their annual conference in Chicago. I am anticipating a number of interesting and important abstracts that will be directly relevant to those of us with advanced prostate cancer. Among the first release of information comes an announcement from Medivation Inc. and Astellas Pharma Inc. who have [...]

By Malecare|2012-06-02T12:08:12-04:00June 2nd, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Enzalutamide (MDV-3100), MDV3100, On The Horizon, Uncategorized|0 Comments